Gadolinium Chloride Improves the Course of Tnbs and Dss-Induced Colitis Through Protecting Against Colonic Mucosal Inflammation

Chao Du,Peng Wang,Yanbo Yu,Feixue Chen,Jun Liu,Yanqing Li
DOI: https://doi.org/10.1038/srep06096
IF: 4.6
2014-01-01
Scientific Reports
Abstract:Inflammatory macrophages in colonic mucosa are the leading drivers of the pathology associated with inflammatory bowel disease (IBD). Here we examined whether gadolinium chloride (GdCl 3 ), a macrophage selective inhibitor, would improve the course of 2,4,6-trinitro benzene sulfonic acid (TNBS) and dextran sodium sulfate (DSS)-induced colitis in mice and the potential mechanisms were investigated. By giving GdCl 3 to colitis mice through intravenous or intrarectal route, we found that GdCl 3 markedly ameliorated the colitis severity, including less weight loss, decreased disease activity index scores and improved mucosal damage. To investigate the potential mechanisms, flow-cytometric analysis was performed to detect the proportion of mucosal macrophages in colon. The results showed that GdCl 3 had no macrophage depletion effect in colonic mucosa, but significantly suppressed TNBS and DSS-induced TNFα, IL-1β and IL-6 secretions. Also, Western blotting analysis indicated that NF-κB p65 expression was significantly attenuated in the mucosa in colitis mice with GdCl 3 treatment. Then, the anti-inflammatory activity of GdCl 3 was confirmed in LPS-stimulated RAW 264.7 cells that GdCl 3 might down-regulate the production of proinflammatory cytokines by macrophages through inhibition of the NF-κB signaling pathway. Therefore, intervention with mucosal inflammatory macrophages may be a promising therapeutic target in IBD.
What problem does this paper attempt to address?